Jones R A, Child J A, Master P S, Scott C S
Department of Haematology, Cookridge Hospital, Leeds, UK.
Scand J Immunol. 1991 Jul;34(1):53-61. doi: 10.1111/j.1365-3083.1991.tb01520.x.
Beta 2-microglobulin (beta 2m) constitutes the common light chain of both the MHC-encoded HLA-ABC molecules and a group of structurally related glycoproteins recognized by antibodies of the first cluster of differentiation (CD1a, CD1b and CD1c). These CD1 antigens appear similar to murine T1 and Qa molecules in terms of structure and tissue distribution, although the question of inter-species homology is controversial. A further group of alloantigens expressed predominantly on T cells has been reported however, with immunogenetic characteristics more closely analogous to the murine T1/Qa system than the CD1 antigens, although their precise identity remains ill-defined. Having previously shown that malignant B cells may express membrane CD1c, we examined leukaemic B-cells corresponding to early lymphoblastic differentiation (null- and common acute lymphoblastic leukaemia) through to the terminal plasma cell stage for the expression of other non-HLA class I beta 2m-associated molecules. It was found that leukaemic B-cells at intermediate/late stages of differentiation, represented by non-Hodgkin's lymphoma (B-NHL) and 'hairy-cell' leukaemia (HCL), had significantly higher beta 2m:HLA-ABC ratios than did the cells from other types of B-cell malignancy. Although leukaemic B cells with a demonstrable non HLA-ABC-associated beta 2m component expressed detectable levels of CD1c, and insignificant levels of CD1a and CD1b, the antigen density was insufficient to account for the excess beta 2m. In vitro stimulation of leukaemic B cells by phorbol ester substantially increased the expression of HLA-ABC and CD1c, but also accentuated further the difference between the expression of these molecules and that of beta 2m. There was no detectable beta 2m other than that associated with HLA-ABC and CD1 on the surface of malignant T cells by contrast. Our findings strongly support the existence, at certain stages of leukaemic B-cell differentiation, of an additional beta 2m component(s) other than that associated with HLA-ABC and CD1.
β2-微球蛋白(β2m)构成了MHC编码的HLA-ABC分子以及一组由分化抗原簇第一组(CD1a、CD1b和CD1c)抗体识别的结构相关糖蛋白的共同轻链。这些CD1抗原在结构和组织分布方面似乎与小鼠T1和Qa分子相似,尽管种间同源性问题存在争议。然而,已报道了另一组主要在T细胞上表达的同种异体抗原,其免疫遗传特征比CD1抗原更类似于小鼠T1/Qa系统,尽管它们的确切身份仍不明确。此前我们已表明恶性B细胞可能表达膜CD1c,我们检测了对应于早期淋巴细胞分化(无和常见急性淋巴细胞白血病)直至终末浆细胞阶段的白血病B细胞中其他非HLAⅠ类β2m相关分子的表达。结果发现,以非霍奇金淋巴瘤(B-NHL)和“毛细胞”白血病(HCL)为代表的白血病B细胞分化中/后期阶段,其β2m:HLA-ABC比值显著高于其他类型B细胞恶性肿瘤的细胞。尽管具有可证实的非HLA-ABC相关β2m成分的白血病B细胞表达了可检测水平的CD1c,以及微不足道水平的CD1a和CD1b,但抗原密度不足以解释过量的β2m。佛波酯对白血病B细胞的体外刺激显著增加了HLA-ABC和CD1c的表达,但也进一步加剧了这些分子与β2m表达之间的差异。相比之下,在恶性T细胞表面除了与HLA-ABC和CD1相关的β2m外未检测到其他β2m。我们的发现有力地支持了在白血病B细胞分化的某些阶段存在除与HLA-ABC和CD1相关之外的其他β2m成分。